Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …

Understanding the molecular landscape of nonmuscle-invasive bladder cancer (NMIBC) is
essential to improve risk assessment and treatment regimens. We performed a …

Urothelial bladder carcinoma (UC) ranks among the top ten most commonly diagnosed
cancers worldwide on an annual basis. The standardized classification system for urothelial …

Molecular subtyping has been a major focus of bladder cancer research over the past
decade. Despite many promising associations with clinical outcomes and treatment …

The precise classification of tumors into relevant molecular subtypes will facilitate both future
research and optimal treatment. In the present investigation, the Lund Taxonomy system for …

Abstract Treatment of bladder cancer patients depends on precise diagnosis. Molecular
subtyping by gene expression profiling may contribute substantially to subclassification of …

Context While urothelial and renal cell cancers have exhibited modest responses to novel
immune checkpoint inhibitors targeting the programmed death ligand 1 and its receptor …

The global incidence of bladder cancer is more than half a million diagnoses each year.
Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC) …

Simple Summary Bladder cancer (BC) possesses distinct molecular profiles that influence
progression depending on its biological nature and delivered treatment intensity. Muscle …